Basic Information
| LncRNA/CircRNA Name | PTAR |
| Synonyms | AP000695.4 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, Western blot |
| Sample | ovarian cancer tissues, cell lines (SKOV3, A2780, OVCAR3) |
| Expression Pattern | up-regulated |
| Function Description | PTAR was significantly up-regulated in the mesenchymal subtype samples compared with the epithelial subtype samples from the TCGA OvCa data sets.Further analysis showed that enhanced expression of PTAR promoted EMT and metastasis through the regulation of miR-101. |
| Pubmed ID | 30098599 |
| Year | 2018 |
| Title | LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. |
External Links
| Links for PTAR | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |